|Articles|October 14, 2019
Characterization and Formulation Screening of mAb and Antibody-Drug Conjugates (ADCs) by High-throughput DLS
Author(s)Wyatt
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Novartis–Avidity Biosciences Deal Highlights Next-Gen RNA Manufacturing Potential
2
AI-Driven Organ-on-Chip Platforms Are Changing the Game in Bio/Pharma R&D
3
RNAnalytics’ Viktoria Enkmann Ponders Nanoparticle Characterization Advances at CPHI Frankfurt: Part One
4
Q&A: An Evolution in Enzyme Engineering with Zymvol’s Marina Cañellas
5
